A total of 242 patients were included with a mean age of 42.4 ± 13 years (range 17 to 76 years). Our study included 127 (52.48%) female patients, i.e. a sex ratio of 0.91. We found 9 (3.71%) diabetics including 04 cases of acromegaly, 02 cases of non-secreting adenomas, 02 cases of mixed adenomas and Cushing’s disease. Arterial hypertension was found in 14 patients (5.78%) including 07 cases of acromegaly, 05 cases of prolactinoma, a non-secreting adenoma and Cushing's disease.

The mean consultation time was 19.7 ± 23 months. This delay was ≥ 12 months in 41.91%.

The clinical symptomatology was dominated by the tumor syndrome (176 cases, 72.72%) represented by 111 cases of headaches (45.86%), 11 cases of pituitary apoplexy (4.54%).

Gonadotropic syndrome was found in 103 patients (42.56%). These were mainly disorders of the menstrual cycle and fertility. Galactorrhea was found in 89 patients (36.77%). Twenty-one (21) patients presented with a dysmorphic syndrome (8.68%) and 15 patients with Cushing's syndrome (6.19%).

On the ophthalmological level, the main abnormalities were the decrease in visual acuity (121 cases, (50%), blindness (30 cases, 12.39%), bitemporalhemianopsia (45 cases, 16.53%). Table 1 shows the distribution of patients according to epidemiological and clinical data.

Biologically, hormonal explorations found normal anterior pituitary function in 126 patients (52.06%). The abnormalities found were isolated hyperprolactinemia (80 cases, 33.05%), isolated central hypercorticism (14 cases, 5.78%), isolated hypersecretion of GH (13 cases, 5.37%), mixed hypersecretion(09 cases, 3.71%). Partial anterior pituitary insufficiency was found in 3 cases, 1.24%.

All patients underwent pituitary imaging. Among them, 123 (50.82%) brain CT scans and 171 (70.66%) magnetic resonance imaging. The morphological anomalies were a macroadenoma in 81.40% (197 patients), a microadenoma in 18.59% (45 cases). Chiasmatic or cavernous extension was found in 22 patients (9.01%). Macroadenomas involved 99.21% (125/126 cases) of non-secreting adenomas, 62.50% (50/80 cases) of prolactin adenomas, 92.31% (12/13 cases) of acromegaly cases and 7.14% (1/14 cases) of Cushing’s disease cases and 100%

(9/9 cases) of mixed secretion adenomas.

Pathologically, it was mainly a non-secreting pituitary adenoma in 126 patients (52.06%), a pure prolactinoma in 80 patients (33.05%). Thirteen patients (5.37%) had acromegaly, 14 patients (5.78%) Cushing’s disease. The pituitary adenoma was of mixed secretion in 9 patients (3.71%). These were hypersecretion of prolactin associated with hypersecretion of GH in 8 cases and central hypercorticism in 01 cases.

Among the cases of acromegaly, non-secreting adenoma and mixed adenoma, the predominance was male in respectively 53.85%, 55.56% and 65.6%. While in the cases of prolactinoma and Cushing’s disease, the female sex represented respectively 78.57% and 78.57 of the cases. Table 2 shows Distribution of the patient profile according to the etiology of pituitary adenomas.

Factors significantly associated with prolactinoma were young age (p = 0.000), female sex (p = 0.000), long consultation delay (p = 0.000) and microadenoma (p = 0.001). Only arterial hypertension was associated with acromegaly (p = 0.000). We found a significant correlation between Cushing’s disease and microadenomas (p = 0.000). Non-secreting adenomas were significantly associated with advanced age, long delay in consultation, male sex, tumor syndrome and macroadenomas. Table 3 shows Representation of factors associated with the etiological forms of adenomas Supported.

Patients received medical and surgical treatment, others had both treatments

(medical and surgical). Only 95 patients (39.25%) had received medical treatment. These were mainly prolactin adenomas and those with mixed secretion. In cases of adenoma with associated prolactin secretion, the first-line medical treatment was based on Cabergoline (Dostinex®) in 85 cases (89.5%), Bromocriptine (Parlodel®) in 8 cases (8, 4%), Quinagoline (Norprolac®) in a single case.

Among our patients, 173 (71.48%) had undergone pituitary surgery. The transphenoidal approach was the most used (166 cases, 95.95%). Four (4) patients had undergone a ventriculoperitoneal bypass (2.31%) and 03 an upper route surgery (1.73%). Only one patient had benefited from external radiotherapy. This surgery involved 65.87% of non-secreting adenomas (83 cases), 85% of prolactinomas (68 cases), 85.71% of Cushing's disease cases (12 cases), and 71.42% of acromegaly cases (15 cases).

Postoperative complications were transient diabetes insipidus in 82 cases (47.39%), leakage of cerebrospinal fluid (20 cases, 11.56%). We had observed 18 cases of death (7.43%). They had an average age of 42 years, a sex ratio of 0.8, an average consultation time of 22.44 months, a tumor syndrome in 16 cases (88.88%), a macroadenoma in 15 cases (83.33 %). These were 03 cases of acromegaly, 08 cases of non-secreting adenomas, 01 cases of Cushing’s disease and 06 prolactinomas. Only 13 patients had undergone pituitary surgery including 02 cases by high way.

One hundred and sixty-four (67.76%) patients had benefited from medium-term hormonal control. Exploration was normal in 130 patients (79.3%). Among the 173 patients operated on, 156 had performed a control MRI (90.17%). The resection was complete in 61.5% of cases. An improvement in ophthalmological explorations was observed in 80.5% of cases.

We report 242 cases of pituitary adenoma from a 14-year multicenter study. This pathology seems to be increasing with a prevalence between 3.9 and 7.4 cases per 100,000 per year [11] . In the United States, Cheng Chen et al. [12] reported 47,030 cases of pituitary adenoma over 12 years. In Morocco, 60 cases of pituitary adenoma were found over a period of 5 years [8] . Beyond a few disparities, the average age of 42.4 years found in our cohort was similar to the data in the literature [13] . The gender profile varies from one study to another and according to the specialty of the authors [8] [12] [13] [14] . The female predominance can be explained by the preponderance of prolactin adenomas more expressive in women by amenorrhea-galactorrhea syndrome.

In our study, the tumor syndrome was composed mainly of visual disturbances and headaches [3] [8] . Of the 242 patients, the endocrine syndrome was dominated by gonadotropic disorders, mainly amenorrhea-galactorrhea syndrome. This corroborates data from the African literature [14] . Its impact on the fertility of the couple directs the patients initially in urology or gynecology according to the sex. The epidemiological part of the other secretory syndromes remains variable from one series to another and according to the specialties [15] [16] .

Worldwide, there is a disparity in the frequency of the two main etiologies of pituitary adenomas, namely prolactinomas and non-functional adenomas [3] [4] [8] [11] [14] . We report a predominance of non-functional adenomas (51.8%), followed by prolactinomas (32.78%). The predominance of secretory forms in series from medical specialties is strongly guided by specific organ disturbances [14] [15] [16] . This would initially push patients into endocrinology, gynecology, and rheumatology.

The role of tumor syndrome in non-functional adenomas explains the predominance of this entity in neurosurgical series [17] . Macroadenomas seem to be more common in male subjects [18] . These macroadenomas partly reflect a delay in consultation of an average of 18 months [3] [15] [19] . Fernandez et al. [15] reported that the delay in diagnosis was more pronounced in male subjects due to the long insidious nature of the symptomatology.

In Senegal, we have real difficulties in accessing somatostatin analogues. The medical treatment of functional pituitary adenomas therefore remains limited to the treatment of prolactinomas and bi-secreting adenomas with dopaminergic agonists [5] [6] [7] [20] [21] . In our series, only 95 patients (39.25%) had received medical treatment with dopaminergic agonists. Under this treatment, Irfan et al. [5] had found a normalization of the prolactin level in 73.2% and a reduction of more than 50% of the tumor volume in 45.8% after two years. In the study by Kars et al. [6] in the Netherlands, it was a normalization of prolactin in 85% and a reduction in tumor volume in 35% of patients. In a series evaluating the impact of medical treatment on prolactin macroadenomas, there was 80% normalization of prolactin, 87% significant reduction in tumor volume and 68% improvement in visual field abnormalities [22] . This reduction in tumor volume was close to 80% [23] , or even 100% in 12% and 45% [24] .

In our study, the management was surgical in 71.7% and the transsphenoidal approach was the most used. In the Netherlands, Kars et al. [6] reported that 35% of cases of prolactinomas required additional surgical treatment. Transsphenoidal pituitary surgery remains the gold standard [8] [25] [26] . However, this approach can be fraught with postoperative complications [27] [28] . Postoperative complications were dominated by transient diabetes insipidus, i.e. 67.9%, then cerebrospinal fluid leak, i.e. 12.5%. Therefore, management requires a personalized, multidisciplinary approach, taking into account each patient's individual health status and response to previous treatment.

The limitations of the study encountered were incomplete clinical records, non-exhaustive postoperative exploration, financial difficulties and a large number of patients lost to follow-up.